Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Wavelength takes stake in Indian drug chemical supplier

by Rick Mullin
February 28, 2021 | A version of this story appeared in Volume 99, Issue 7

 

The Israeli drug services firm Wavelength Pharmaceuticals has acquired a majority stake in Vanamali Organics, a maker of drug starting materials based in Telangana, India. In a press release, Wavelength CEO Iftach Seri says the deal is intended to secure access to chemicals in “an increasingly unpredictable world” where supply chain control has become a “key strategic concern.” Wavelength says it produces 250 metric tons per year of active pharmaceutical ingredients, including highly potent and cytotoxic substances.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.